VNDA

Insider Trades

Name	Value	Action	Price	Current Price
Polymeropoulos Mihael HristosDirector, Officer, Other: President And CEO $1.3M156.2k shares SellMar 2, 2026 $8.17 --
Birznieks GuntherSVP, Business Development $351k42.4k shares SellMar 2, 2026 $8.27 --
Moran Kevin PatrickSVP, CFO & Treasurer $351k42.4k shares SellMar 2, 2026 $8.27 --
Williams TimothySVP & General Counsel $351k42.4k shares SellMar 2, 2026 $8.27 --
Wijkstrom JoakimSVP, Chief Marketing Officer $255k30.8k shares SellMar 2, 2026 $8.27 --
Honore TageDirector $241k30k shares SellFeb 23, 2026 $8.03 --

News

prnewswire.comVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasisprnewswire.comMay 27

seekingalpha.comVanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Missseekingalpha.comMay 13

prnewswire.comVanda Pharmaceuticals Announces Participation at May 2026 Investor Conferencesprnewswire.comMay 7

seekingalpha.comVanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

zacks.comVanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 6

Trade VNDA

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

CEO: Mihael H. Polymeropoulos
IPO Date: Apr 12, 2006

Market Data

Open: $6.01
High: $6.12
Low: $5.75
Volume: 1.6M
Avg Volume: 1.3M
52W High: $9.94
52W Low: $4.14

Valuation

Market Cap: $349M
Enterprise Value: $308M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-110M
Revenue: $216M
Net Income: $-220M
Cash: $85M
Debt: $13M

Events

EarningsJul 30

EPS est. -0.5825